Ibrutinib, a first-generation inhibitor of BTK, was approved in 2013 and has shown noteworthy clinical activity in lymphoid malignancies, such as chronic lymphocytic leukaemia (CLL) [5] and mantle cell lymphoma (MCL) [6]. This evidence concerns the gene BTK and mantle cell lymphoma.